| Literature DB >> 34262158 |
Joana Barros-Martins1, Swantje I Hammerschmidt1, Anne Cossmann2, Ivan Odak1, Metodi V Stankov2, Gema Morillas Ramos2, Alexandra Dopfer-Jablonka2,3, Annika Heidemann2, Christiane Ritter1, Michaela Friedrichsen1, Christian Schultze-Florey1,4, Inga Ravens1, Stefanie Willenzon1, Anja Bubke1, Jasmin Ristenpart1, Anika Janssen1, George Ssebyatika5, Günter Bernhardt1, Jan Münch6, Markus Hoffmann7,8, Stefan Pöhlmann7,8, Thomas Krey5,9, Berislav Bošnjak10, Reinhold Förster11,12,13, Georg M N Behrens14,15,16.
Abstract
Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca's ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School's COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer's BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.Entities:
Year: 2021 PMID： 34262158 DOI： 10.1038/s41591-021-01449-9
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440